No s'ha trobat cap coincidència exacta per Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG, però canviant-lo per Management of Aromatase Inhibitor Associated Bone Loss AIBL in postmenopausal women with hormone sensitive breast cancer Joint position statement of the IOF CABS ECTS IEG ESCEO IMS and SIOG...
Resultats globals: 1 registres trobats en 0.14 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
12 p, 675.8 KB Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer : Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG / Hadji, Peyman (Krankenhaus Nordwest) ; Aapro, Matti S. (Genolier Cancer Center, Switzerland) ; Body, Jean-Jacques (CHU Brugmann, Université Libre de Bruxelles, Belgium) ; Gnant, Michael (Medical University of Vienna, Austria) ; Brandi, Maria Luisa (University of Florence, Italy) ; Reginster, Jean Yves (University of Liège, Belgium) ; Zillikens, M. Carola (Erasmus MC, Rotterdam, Netherlands) ; Glüer, Claus-C. (Univeristy of Kiel, Germany) ; de Villiers, Tobie (University of Stellenbosch, Cape Town, South Africa) ; Baber, Rod (University of Sydney, Australia) ; Roodman, G. David (Indiana University School of Medicine, USA) ; Cooper, Cyrus (University of Southampton, UK) ; Langdahl, Bente (Aarhus University, Denmark) ; Palacios, Santiago (Instituto Palacios Madrid, Spain) ; Kanis, John (Catholic University of Australia, Melbourne, Australia and University of Sheffield, UK) ; Al-Daghri, Nasser (University of Riyadh, Saudi Arabia) ; Nogués Solán, Xavier (Universitat Autònoma de Barcelona) ; Eriksen, Erik Fink (University of Oslo, Norway) ; Kurth, Andreas (Klinikum Birkenwerder, Germany) ; Rizzoli, Rene (Geneva University, Switzerland) ; Coleman, Robert E. (University of Sheffield, UK)
Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). [...]
2017 - 10.1016/j.jbo.2017.03.001
Journal of Bone Oncology, Vol. 7 (June 2017) , p. 1-12  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.